Skip to content
Review Open access

Targeting DNA gyrase B: medicinal chemistry strategies to combat antimicrobial resistance.

Aug 2026 · RSC Medicinal Chemistry · 0 citations
Medicine

TL;DR

This review comprehensively summarizes the design, synthesis, biological evaluation, and structure-activity relationships of heterocyclic GyrB inhibitors, highlighting the therapeutic potential of quinoline, thiazole, pyrrole, benzimidazole, benzofuran, azaindole, benzothiazole, pyrazole, pyridine, and related scaffolds.

Abstract

Antimicrobial resistance (AMR) represents one of the most pressing global healthcare challenges, necessitating the discovery of novel antibacterial agents with distinct mechanisms of action. DNA gyrase, an essential bacterial type II topoisomerase absent in humans, has emerged as an attractive antibacterial target. In particular, the ATPase domain of the GyrB subunit is highly conserved across ESKAPE pathogens, providing a strong rationale for the development of broad-spectrum antibacterial agents. Several natural product-derived antibiotics, including novobiocin, clorobiocin, and coumermycin A1, are well-established GyrB inhibitors that share a common 3-amino-4-hydroxycoumarin pharmacophore responsible for key interactions with residues such as Glu50, Arg76, Pro79, and Arg136 within the ATP-binding pocket. To improve potency and overcome resistance, diverse medicinal chemistry strategies, including scaffold hopping, bioisosteric replacement, linker rigidification, and pharmacophore hybridization, have been employed to develop novel ATP-competitive GyrB inhibitors. These approaches have led to compounds with enhanced enzyme inhibition, improved suppression of bacterial DNA supercoiling, and superior minimum inhibitory concentration (MIC) values. This review comprehensively summarizes the design, synthesis, biological evaluation, and structure-activity relationships of heterocyclic GyrB inhibitors, highlighting the therapeutic potential of quinoline, thiazole, pyrrole, benzimidazole, benzofuran, azaindole, benzothiazole, pyrazole, pyridine, and related scaffolds. In addition, recent advances in resistance mechanisms, translational challenges, and clinically advanced GyrB inhibitors are discussed, providing a comprehensive perspective to guide the rational design of next-generation antibacterial agents for combating antimicrobial resistance.

Read PDF

Similar papers

Review Open access Sep 2026

Coumarin derivatives combating antibacterial resistance: molecular modeling-driven insights and comprehensive SAR elucidation targeting DNA gyrase and topoisomerase IV.

Overall, the collective evidence establishes coumarin as a highly adaptable scaffold for the development of next-generation antibacterial agents and highlights integrated structure-based design, dual-target inhibition, and comprehensive biological validation as key priorities for future medicinal chemistry research.

Aanchal Khanna, Karanvir Singh, Alok Raj et al. · 0 citations
Review Aug 2026

Isatin-based Strategies for Microbial Infections: A Multifaceted Perspective.

The therapeutic potential of isatin and its derivatives against bacterial, fungal, viral, and microbacterial diseases is well highlighted in this study.

Radhika Sharma, Manjot Singh, Pushp Kashyap et al. · 0 citations
Open access Sep 2026

In vitro evaluation of novel consensus-sequence-generated Brevinin-2 antimicrobial peptides

The consensus-sequence approach toward novel Brevinin-2 AMP discovery via alignment combined with in vitro antimicrobial analysis shows promise to test and initially validate other peptides, and establishes a streamlined pipeline for Brevinin-2 peptide development.

Colin M. McDowell, Jessica D. Carder, J. Brozik et al. · 0 citations
Review Open access Sep 2026

Gramicidin S analogues as a pathway to overcome antimicrobial resistance.

The growing occurrence of antimicrobial resistance represents a major challenge to global healthcare and necessitates the development of novel therapeutic agents capable of overcoming multidrug-resistant (MDR) pathogens. Gramicidin S (GS), a cyclic decapeptide antibiotic has attracted renewed interest as a promising te...

T. S. Shkuratova, Daria V. Andreeva, A. Tikhomirov et al. · 0 citations
Open access Sep 2026

Fragment-based drug discovery strategy reveals an unprecedented allosteric binding site in Mycobacterium tuberculosis DNA gyrase.

Tuberculosis remains a serious public health threat and the leading infectious cause of death worldwide. Tuberculosis treatment requires at least four antimicrobial drugs and is associated with adverse effects and prolonged therapy, compromising adherence and increasing the risk of drug resistance. Therefore, developin...

Sabrina T. Shiroma, Nicolas O. Rossini, Jillian F. Armenia et al. · 0 citations
Open access Sep 2026

All-atoms MD simulations study of newly designed ciprofloxacin derivatives as potential bacterial DHPS and DNA gyrase inhibitors

A series of ciprofloxacin-sulfonamide hybrid molecules was designed, in which each pharmacophore retains its established mechanism of action and CIS4, CIS5, and CIS12 emerged as the most promising dual-target inhibitor of bacterial DHPS and DNA gyrase.

Chita Ranjan Sahoo, Madhusmita Rout, S. Paidesetty et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.